Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure

Cardiovascular Drugs and Therapy

Volumn 12, Issue 5, 1998, Pages 483-486

  Fauchier, Laurent ^a   Babuty, Dominique ^a   Autret, Marie Laurence ^a   Poret, Philippe ^a   Cosnay, Pierre ^a   Fauchier, Jean Paul ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Flecainide; Heart rate variability

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TACHYCARDIA; VAGUS NERVE STIMULATION; WOLFF PARKINSON WHITE SYNDROME;

ADOLESCENT; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; FLECAINIDE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE;

EID: 0032438783     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007710301259     Document Type: Article

References (26)

1. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurements, physiological interpretation, and clinical use. Circulation 1996;93: 1043-1065.
2. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991:84:482-492.
3. Kleiger RE, Miller JP, Bigger JT Jr. et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59:256-262.
4. Bigger JT Jr., Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-171.
5. Cripps TR, Malik M, Farrell TG, Camm AJ. Prognostic value of reduced heart rate variability after myocardial infarction: Clinical evaluation of a new analysis method. Br Heart J 1991;65:14-19.
6. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993;88:180-185.
7. Fei L, Anderson MH, Katritsis D, Sneddon J, Statters DJ, Malik M, Camm AJ. Decreased heart rate variability in survivors of sudden cardiac death not associated with coronary artery disease. Br Heart J 1994;71:16-21.
8. Coumel P. Neural aspects of paroxysmal atrial fibrillation. In Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press, 1992:109-125.
9. Coumel P, Leenhardt A, Leclercq JF. Autonomic influences on ventricular arrhythmias in myocardial hypertrophy and heart failure. Circulation 1993;87(Suppl. VII):VII84-VII91.
10. Sandrone G, Mortara A, Torzillo D, La Rovere MT, Malliani A, Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994;74:340-345.
11. Molgaard H, Mickley H, Pless P, Bjerregaard P, Moller M. Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction. Am J Cardiol 1993;71: 1357-1359.
12. Pousset F, Copie X, Lechat P, et al. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol 1996;77: 612-617.
13. Cook JR, Bigger JT Jr., Kleiger RE, Fleiss JL, Steinman RC, Rolnitzky LM. Effect of atenolol and diltiazem on heart period variability in normal persons. J Am Coll Cardiol 1991;17:480-484.
14. Lombardi F, Torzillo D, Sandrone G, et al. Beta-blocking effect of propafenone based on spectral analysis of heart rate variability. Am J Cardiol 1992;70:1028-1034.
15. Antimisiaris M, Sarma JS, Schoenbaum MP, Sharma PP, Venkataraman K, Singh BN. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: Significance for the control of sudden cardiac death. Am Heart J 1994;128:884-891.
16. Hohnloser SH, Klingenheben T, Zabel M, Just H. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. Am J Cardiol 1993;72:67A-71A.
17. Bigger JT Jr., Rolnitzky LM, Steinman RC, Fleiss JL. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. J Am Coll Cardiol 1994;23:733-740.
18. Akhtar M, Breithardt G, Camm AJ, et al. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1990;81: 1123-1127.
19. Josephson MA, Ikeda N, Singh BN. Effects of flecainide on ventricular function: Clinical and experimental correlations. Am J Cardiol 1984;53:95B-100B.
20. Falk RH, Fogel RI. Flecainide. J Cardiovasc Electrophysiol 1994;5:964-981.
21. Zuanetti G, Ewing DJ, Schwartz PJ, Neilson JM, Latini R. Heart rate variability in patients with ventricular arrhythmias: Effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG). J Am Coll Cardiol 1991; 17:604-612.
22. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 1989;80: 1571-1579.
23. Alboni P, Paparella N, Cappato R, Candini G. Direct and autonomically mediated effects of oral flecainide. Am J Cardiol 1988;61:759-763.
24. Pritchett EL, Hougham AJ, McCarville SE, Platt ML, DaTorre SD. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol 1991;17: 297-303.
25. Padrini R, Ferrari M, Maiolino P, al-Bunni M, Busa M, Piovan D. Pharmacodynamic variability of flecainide assessed by QRS changes. Clin Pharmacol Ther 1993; 53:59-64.
26. Malik M, Camm AJ. Components of heart rate variability -What they really mean and what we really measure. Am J Cardiol 1993;72:821-822.